Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15101 - 15125 of 15147 in total
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational
Investigational
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).
Investigational
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Vet approved
Matched Iupac: … 'R,7aR)-6-{[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4S,5S,6S)-6-[(2R,3aS,3'aR,6'R,7R,7'S,7aR,7'aR)-7'-acetyl-6'-methyl
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
Investigational
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
Investigational
INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Investigational
UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.
Investigational
ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
Investigational
Investigational
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
Investigational
R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
Investigational
R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Investigational
Displaying drugs 15101 - 15125 of 15147 in total